Peptide mixture
There is disclosed a peptide mixture suitable for eliciting an immune response. It comprises a first and a second peptide, each corresponding to a fragment of the RAS protein. Each of the first and second peptides comprises a region of at least 8 amino acids which includes position 13 of the RAS protein. Each of said regions of the first and second peptides independently has at least 6 amino acid residues, other than at said position 13, which are identical to the corresponding region of the RAS protein. Each of the first and the second peptides has a point mutation at the amino acid corresponding to said position 13. The point mutation of the first peptide is different from the point mutation of the second peptide.
1. A peptide mixture suitable for eliciting an immune response comprising a first, a second a third, a fourth, a fifth, a sixth, a seventh and an eighth, peptide, each corresponding to a fragment of the RAS protein wherein:
the first, second, third, fourth, fifth, sixth, seventh and eighth peptides are:
a peptide comprising the amino acid sequence of SEQ ID NO: 19,
a peptide comprising the amino acid sequence of SEQ ID NO: 20,
a peptide comprising the amino acid sequence of SEQ ID NO: 21,
a peptide comprising the amino acid sequence of SEQ ID NO: 22,
a peptide comprising the amino acid sequence of SEQ ID NO: 23,
a peptide comprising the amino acid sequence of SEQ ID NO: 24,
a peptide comprising the amino acid sequence of SEQ ID NO: 25, and
a peptide comprising the amino acid sequence of SEQ ID NO: 26;
and wherein
each peptide comprises no more than 30 amino acids.
2. A pharmaceutical composition comprising the peptide mixture according to claim 1 and a pharmaceutically acceptable carrier, diluent and/or excipient.
3. A peptide mixture according to claim 1 , for use in inducing an immune response against cancer, wherein the cancer is colorectal, lung and/or pancreatic cancer.
4. A pharmaceutical composition according to claim 2 , for use in for use in inducing an immune response against cancer, wherein the cancer is colorectal, lung and/or pancreatic cancer.
5. A peptide mixture suitable for eliciting an immune response comprising a first, a second, a third, a fourth, a fifth and a sixth peptide, each corresponding to a fragment of the RAS protein, wherein:
the first, second, third, fourth, fifth and sixth peptides are:
a peptide comprising the amino acid sequence of SEQ ID NO: 27,
a peptide comprising the amino acid sequence of SEQ ID NO: 28,
a peptide comprising the amino acid sequence of SEQ ID NO: 29,
a peptide comprising the amino acid sequence of SEQ ID NO: 30,
a peptide comprising the amino acid sequence of SEQ ID NO: 31, and
a peptide comprising the amino acid sequence of SEQ ID NO: 32,
and wherein each of the peptides comprises no more than 30 amino acids.
6. A pharmaceutical composition comprising the peptide mixture according to claim 5 and a pharmaceutically acceptable carrier, diluent and/or excipient.
7. A peptide mixture according to claim 5 , for use in inducing an immune response against cancer, wherein the cancer is colorectal, lung and/or pancreatic cancer.
8. A pharmaceutical composition according to claim 6 , for use in inducing an immune response against cancer, wherein the cancer is colorectal, lung and/or pancreatic cancer.